| NCT ID | NCT06070766 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RIVER Foundation |
| Condition | Chronic Condition |
| Study Type | OBSERVATIONAL |
| Enrollment | 50,000 participants |
| Start Date | 2023-10-01 |
| Primary Completion | 2028-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50,000 participants in total. It began in 2023-10-01 with a primary completion date of 2028-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multiple site studies with the recruitment of other sub-investigators and sites. It's sobering to consider how chronic illness makes us more vulnerable to suicidal thoughts and behavior. However, the existence of multiple risk factors also means that there are numerous ways to intervene. Addressing and improving even one risk area will reverberate and improve other areas and the quality of life. RIVER Foundation is completing a 500-participant pilot study researching the safety of oral and nasal ketamine at home with no therapy. The pilot study examined three psychological scales: P.H.Q. 9, G.A.D. 7, and PCL5 scores. The interim report will be available in Nov 2023 with a final report in June 2024. The lack of knowledge for the average medical practitioner makes ketamine a boutique medicine, often costly and unaffordable to those in need. Yet daily medical providers are eliminating ketamine as a choice in the treatment of chronic conditions. The pilot study demonstrated the who, and where. The who, was adults with a chronic condition. The pilot study demonstrated the majority of those who could use ketamine are not receiving it due to cost. According to the 500-participant study, ketamine is safe and effective for at-home use thus demonstrating the where (at home with no supervision).
Eligibility Criteria
Inclusion Criteria: Must have an identifiable chronic condition. Exclusion Criteria: Healthy Population
Contact & Investigator
Dharma Rose, D.O. M.S.
PRINCIPAL INVESTIGATOR
RIVER Foundation
Frequently Asked Questions
Who can join the NCT06070766 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Condition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06070766 currently recruiting?
Yes, NCT06070766 is actively recruiting participants. Contact the research team at ed@riverofchange.org for enrollment information.
Where is the NCT06070766 trial being conducted?
This trial is being conducted at Bigfork, United States, Helena, United States.
Who is sponsoring the NCT06070766 clinical trial?
NCT06070766 is sponsored by RIVER Foundation. The principal investigator is Dharma Rose, D.O. M.S. at RIVER Foundation. The trial plans to enroll 50,000 participants.